ReviewSeminars in oncology2015
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.
Review in Seminars in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Impact of the tumor microenvironment on survival in anaplastic thyroid carcinoma.Scientific reports · 2025Article
- Article
- Cinobufagin Inhibits Invasion and Migration of Non-Small Cell Lung Cancer via Regulating Glucose Metabolism Reprogramming in Tumor-Associated Macrophages.Drug design, development and therapy · 2025Article
- Innate Immune Response to Monkeypox Virus Infection: Mechanisms and Immune Escape.Journal of innate immunity · 2024Review
- TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy.Communications biology · 2023Article
- Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy.International review of cell and molecular biology · 2023Article
- Roles and new Insights of Macrophages in the Tumor Microenvironment of Thyroid Cancer.Frontiers in pharmacology · 2022Review
- The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?Cancer immunology, immunotherapy : CII · 2021Review
- A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications.Translational lung cancer research · 2021Review
- Circadian clock: a regulator of the immunity in cancer.Cell communication and signaling : CCS · 2021Review
- C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights.Frontiers in immunology · 2020Review
- STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.Journal for immunotherapy of cancer · 2019Article
- Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor.Polymers · 2018Article
- Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.Journal of experimental & clinical cancer research : CR · 2018Article
- N-Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen-Presenting Cells through Dectin-1 and Dectin-2.Angewandte Chemie (International ed. in English) · 2018Article
- Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression.Cell death discovery · 2018Article
- Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.Frontiers in immunology · 2018Article
- Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells.Oncotarget · 2017Article
- Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Given recent technological advances and advances in our understanding of cancer, immunotherapy of cancer is being used with clear clinical benefit. The immunosuppression accompanying cancer itself, as well as with current cancer treatment with radiation or chemotherapy, impairs adaptive immune effectors to a greater extent than innate effector cells. In addition to being less suppressed, innate immune cells are capable of being enhanced via immune-stimulatory regimens. Most strategies being investigated to promote innate immune responses against cancer do not require complex, patient-specific, ex vivo cellular or molecular creation of therapeutic agents; thus they can, generally, be used as "off the shelf" therapeutics that could be administered by most cancer clinics. Successful applications of innate immunotherapy in the clinic have effectively targeted components of the innate immune response. Preclinical data demonstrate how initiation of innate immune responses can lead to subsequent adaptive long-term cancer immunity. We hypothesize that integration of innate immune activation strategies into combination therapies for cancer treatment will lead to more effective and long-term clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.